Full Press Release Details
ICON Acquires Oxford Outcomes
Leading International Health Outcomes Consultancy to become part of
New Late Phase and Outcomes Research Unit
Dublin, Ireland, January 14th, 2011 - ICON plc, (NASDAQ:ICLR)
(ISIN:IE0005711209), a global provider of outsourced development
services to the pharmaceutical, biotechnology and medical device
industries, today announced the expansion of its Late Phase and Outcomes
Research services through the acquisition of Oxford Outcomes, a leading
international health outcomes consultancy. Elizabeth Thiele, formerly
ICON's Executive Vice President of Business Development, has been
appointed President of this specialised service unit.
Headquartered in Oxford, UK, and with offices in the USA and Canada,
Oxford Outcomes provides specialist services in the areas of patient
reported outcomes (PRO), health economics, epidemiology and translation
and linguistic validation.
Commenting on the acquisition, Peter Gray, CEO at ICON plc, said, "The
biopharmaceutical industry and regulators are more than ever before
using post-marketing studies to demonstrate efficacy and safety, as well
as demonstrating the economic value of products. Oxford Outcomes has
grown to become a leader in its field and brings to ICON a wealth of
expertise in the fields of health economics, outcomes research and
epidemiology and a strong reputation for excellent client service."
"We are really excited about joining ICON," commented Paul Quarterman,
Group Managing Director of Oxford Outcomes. "The demand for health
outcomes services has never been greater and merging with ICON gives us
the opportunity to effectively integrate clinical development with
outcomes research on a global scale. Blending the knowledge and
expertise from both companies will lead to powerful, market-leading
client solutions, both in the post-marketing arena and earlier in the
development process."
Elizabeth Thiele, President, Late Phase & Outcomes Research, at ICON
commented, "Oxford Outcomes' demonstrated excellence in late phase and
outcomes research has allowed it to build a blue chip client base, which
includes the world's top-tier pharmaceutical, biotechnology and medical
device companies. We look forward to building on these long-standing
relationships and to offering existing ICON clients a more in-depth
suite of outcomes services."
Fairmount Partners served as financial advisors to Oxford Outcomes in
ICON plc is a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries. The Company
specialises in the strategic development, management and analysis of
programs that support clinical development - from compound selection to
Phase I-IV clinical studies. ICON currently has around 7,800 employees,
operating from 72 locations in 39 countries.
Further information is available at www.iconplc.com
Sam Farthing, VP Investor Relations, ICON plc
Tel: 1-888-381-7923 / +
Ciaran Murray Chief Financial Officer, ICON plc
Vice President, Corporate
Tel: + 353 -1-291-2000